0000000000021404

AUTHOR

Gaetano Inserra

0000-0002-0986-402x

showing 7 related works from this author

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct

Inflammation and Aortic Stiffness: An Individual Participant Data Meta‐Analysis in Patients With Inflammatory Bowel Disease

2017

Background The recent finding that aortic pulse wave velocity ( aPWV ) is increased in patients with inflammatory bowel disease may explain why the cardiovascular risk is increased despite the low prevalence of traditional cardiovascular risk factors. We aimed to test whether inflammation is associated with aortic stiffening in this setting after adjustment for major confounders and to perform subgroup analyses. Methods and Results A systematic literature search for aPWV in inflammatory bowel disease was performed using PubMed, Scopus, Web of Science, and Google Scholar databases (last accessed May 7, 2017). Inclusion criterion was peer‐reviewed publications on clinical studies reporting o…

medicine.medical_specialtySettore MED/09 - Medicina Internapulse wave velocitycardiovascular complicationsBlood SedimentationPulse Wave Analysis030204 cardiovascular system & hematologyStandard scoreInflammatory bowel diseaseLeukocyte Count03 medical and health sciencesVascular Stiffness0302 clinical medicineCrohn DiseaseRisk FactorsInternal medicinemedicineHumansArterial stiffness; Cardiovascular complications; Crohn's disease; Inflammation; Pulse wave velocity; Ulcerative colitis; Cardiology and Cardiovascular Medicine030212 general & internal medicineulcerative colitisInflammationSystematic Review and Meta‐AnalysisCrohn's diseasemedicine.diagnostic_testbusiness.industryMeta Analysisinflammation aortic stiffnessPrognosismedicine.diseaseUlcerative colitisConfidence intervalCrohn's diseaseC-Reactive Proteinarterial stiffnessCardiovascular DiseasesMeta-analysisErythrocyte sedimentation rateMultivariate AnalysisHypertensionLinear ModelsPhysical therapyArterial stiffnessColitis UlcerativeInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of the American Heart Association
researchProduct

Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Si…

2020

BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, with more frequent complications than younger patients. The objective of this study was to assess persistence on therapy and the safety of anti-TNF therapy in older patients (aged ≥ 60 years). METHODS: We retrospectively reviewed the database of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), extracting data regarding IBD patients aged ≥ 60 years and controls < 60 years of age at their first course of anti-TNF treatment. Data concerning persistence on therapy over the first year of treatment (primary objective) together …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaDrug-Related Side Effects and Adverse ReactionsKaplan-Meier EstimateAnti-Tumour Necrosis FactorDiseaseInflammatory bowel diseaseCohort Studies03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Treatment Failure030212 general & internal medicineAdverse effectAgedRetrospective StudiesAged 80 and overTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabAge FactorsAntibodies MonoclonalRetrospective cohort studyMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisInfliximabSicilian Network for Inflammatory Bowel Diseases (SN-IBD).Withholding TreatmentConcomitantFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryCohort studyDrugs & Aging
researchProduct

Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease

2019

Background Inflammatory bowel disease ( IBD ) is characterized by a low prevalence of traditional risk factors, an increased aortic pulse‐wave velocity ( aPWV ), and an excess of cardiovascular events. We have previously hypothesized that the cardiovascular risk excess reported in these patients could be explained by chronic inflammation. Here, we tested the hypothesis that chronic inflammation is responsible for the increased aPWV previously reported in IBD patients and that anti‐TNFa (anti‐tumor necrosis factor‐alpha) therapy reduce aPWV in these patients. Methods and Results This was a multicenter longitudinal study. We enrolled 334 patients: 82 patients with ulcerative colitis, 85 pati…

MaleLongitudinal studyTime FactorsSettore MED/09 - Medicina InternaAorta ThoracicBlood Pressure030204 cardiovascular system & hematologyGastroenterologyInflammatory bowel diseaseulcerative coliti0302 clinical medicineRisk Factorsarterial stiffneVascular DiseaseTumor necrosis factor-alphaEndoscopy Digestive SystemProspective Studies030212 general & internal medicinePulse wave velocityOriginal ResearchCrohn diseasetumor necrosis factor‐alphaUlcerative colitisC-Reactive Proteinarterial stiffnessCardiovascular DiseasesHypertensionFemaleTumor necrosis factor alphamedicine.symptomCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtypulse wave velocityInflammationPulse Wave Analysis03 medical and health sciencesVascular StiffnessInternal medicinemedicineHumansIn patientulcerative colitisbusiness.industryInflammatory Bowel Diseasesmedicine.diseasearterial stiffness; Crohn disease; inflammation; pulse wave velocity; tumor necrosis factor‐alpha; ulcerative colitis; Cardiology and Cardiovascular MedicineinflammationArterial stiffnessbusinessBiomarkersFollow-Up Studies
researchProduct

Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammator…

2019

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Syste…

MaleDiseaseConstriction PathologictumoursInflammatory bowel diseaseLate Onset DisordersCohort Studiessurgery0302 clinical medicineCrohn DiseaseLate Onset DisordersMedicineYoung adultDigestive System Surgical ProceduresCrohn's diseaseGastroenterologyIleitisMiddle AgedColitisItaly030220 oncology & carcinogenesisoutcome030211 gastroenterology & hepatologyFemaleColorectal NeoplasmsCohort studysteroidsAdultmedicine.medical_specialtyAdolescentcomorbiditieselderly03 medical and health sciencesYoung AdultInternal medicineIntestinal FistulaHumansImmunologic FactorsGlucocorticoidsAgedRetrospective StudiesPolypharmacyHepatologybusiness.industrythiopurinesRetrospective cohort studymedicine.diseasecomorbidities; elderly; outcome; steroids; surgery; thiopurines; tumoursPolypharmacyTumor Necrosis Factor Inhibitorsbusiness
researchProduct

Pulse wave velocity differs between ulcerative colitis and chronic kidney disease

2017

Background: We hypothesized that a reversal of the physiological stiffness gradient, previously reported in end-stage renal disease, begins in the early stages of chronic kidney disease (CKD) and that chronic inflammation produces a different arterial phenotype in patients with ulcerative colitis (UC). Objectives: To assess the extent of arterial stiffening in the central (carotid-femoral pulse wave velocity, cf.-PWV) and peripheral arteries (carotid-radial pulse wave velocity, cr-PWV) and to explore the determinants of the stiffness gradient in UC and in CKD. Methods: We enrolled 45 patients with UC, 45 patients with stage 3-4 CKD and 45 matched controls. Results: Despite the comparable cf…

MalePathologyDisease030204 cardiovascular system & hematologyurologic and male genital diseases0302 clinical medicine030212 general & internal medicineStage (cooking)ChildPulse wave velocityAged 80 and overArterial stiffness; Chronic renal failure; Inflammation; Pulse wave velocity; Stiffness mismatch; Ulcerative colitis; Internal MedicineMiddle AgedUlcerative colitisArterial stiffnessPeripheralArterial stiffnecardiovascular systemCardiologyFemalemedicine.symptomGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentInflammationPulse Wave Analysis03 medical and health sciencesYoung AdultVascular StiffnessInternal medicinemedicineChronic renal failureInternal MedicineHumansRenal Insufficiency ChronicAgedInflammationUlcerative colitibusiness.industrymedicine.diseasePulse wave velocityCross-Sectional StudiesUlcerative colitisCase-Control StudiesMultivariate AnalysisArterial stiffnessLinear ModelsColitis UlcerativeStiffness mismatchbusinessKidney disease
researchProduct

A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Di…

2019

Background and aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naive and non-naive patients. Results A total of 632 patients [735 total treatments] were included. Among naive patients, a cli…

0301 basic medicineAdultMalemedicine.medical_specialtyInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseGastrointestinal AgentsInternal medicinemedicineAdalimumabHumansYoung adultSicilypropensity scoreCrohn's diseasebusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabGeneral MedicineOdds ratiomedicine.diseaseAdalimumab; infliximab; propensity score; Adalimumab; Adult; Crohn Disease; Female; Gastrointestinal Agents; Humans; Infliximab; Male; Propensity Score; Sicily; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultInfliximab030104 developmental biologyTreatment OutcomeCohortPropensity score matching030211 gastroenterology & hepatologyFemalebusinessinfliximabmedicine.drug
researchProduct